Women from Appalachia who haven't had access to higher education or whose circumstances have left them in poverty, shame or some other financial or personal predicament often feel a sense of hopelessness about the future.
The seven ladies from Bluefield College's 2014 graduating class of the New Opportunity School for Women.
The ladies from Bluefield College's New Opportunity School for Women celebrate graduation with a group hug following their commencement ceremony.
That's all changing, thanks to the New Opportunity School for Women at Bluefield College, especially for seven aspiring women who graduated from the program this summer. These seven women are now ready to confront their circumstances, overcome their conditions, and pave the way for a new and better life.
Bluefield College announced the creation of its New Opportunity School for Women (NOSW) in January of 2013. Founded by Jane B. Stephenson in 1987 at Berea College in Kentucky, out of an urgent need to help women in Appalachia become better educated and employed, the NOSW is designed to improve the educational, financial and personal circumstances of low-income, under-educated, middle-aged women in the Appalachian region.
The NOSW expanded to a second site at Lees-McCrae College in North Carolina in 2005, and then into the Appalachian regions of Virginia and West Virginia through theestablishment of the third location at Bluefield College. Nine ladies completed the BC program last year. Seven new women graduated this summer, celebrating not only an historic moment for the college, but also a milestone moment for a group of disadvantaged, yet determined women.
The seven Appalachian women, ages 30-55, completed a near-month of intense professional and personal development designed to prepare them for a new life and new opportunities. They took part in a variety of career, educational and cultural improvement activities during the three-week residential program. With a sincere interest to learn and improve their lives, despite past failures and hardships and current difficult circumstances, the ladies spent 50 hours per week in workshops, classes, internships and study trips, all for the purpose of becoming more self-sufficient.
For professional development, the ladies attended workshops on computer basics, grammar, punctuation, and basic math. They also took part in seminars on leadership, career assessment, and public speaking.
As part of the professional development, the women also completed a series of job skills courses where they learned how to develop a resume and write a cover letter. In addition, they participated in mock interviews and work internships at Bluefield College and in the community.
For personal development, the ladies examined women's health issues, legal issues for women, and violence associated with women. They also attended seminars on fashion, beauty tips, and self-esteem. In fact, the personal development activities included makeovers, physical exams, health screenings, and individual private counseling sessions.
Off campus, the New Opportunity School featured cultural development activities for the ladies, focusing on Appalachian literature, creative writing, art and quilting, and including trips to cultural sites around the region.
Following the completion of the summer 2014 program, the women were honored during a graduation ceremony on the Bluefield College campus, where they received diplomas and were asked to give a speech reflecting upon their experiences in the NOSW. During the ceremony, Rev. David Taylor, BC's vice president for development, spoke about how the college's mission closely resembles the New Opportunity School mission.
In addition to resources provided by Bluefield College, the New Opportunity School for Women and local women's access to it are made possible by generous donors who support the school. Donors for 2014 include the Bob Evans Restaurant, Dr. Donald W. Caudill and the Alfred and Shirley Wampler Caudill Fund, Christ Episcopal Church, Frank Litz Smoot Charitable Foundation, George M. Cruise Charitable Foundation, Mrs. Mary M. Glah, Mrs. Sherry R. Hester, Mrs. Crystal W. Kieloch, Dr. and Mrs. David W. Olive, Mrs. Jennifer M. Palmer, Saunders Staffing, Inc., Ms. Jane B. Stephenson, The 1912 Charitable Foundation, Mr. and Mrs. Eli Jones, Grosses Creek Baptist Church, the Bland Ministry Center, Labor of Love, and The Virginia Workforce Investment Board.
Meals for the women attending the 2014 summer session were provided by Valley Food Services, David and Lisa Taylor, the BC Advancement Office, Sandy Tyson and the Grace in Motion Circle, The Virginia Workforce Investment Board, Darrel Blankenship, Tammy Pennington, Beth Walker, Melissa Quillen, the Adult Protective Services Unit at the Tazewell County Department of Social Services, Karen Rich, Linda Martin, Mike Wade with Chick-Fil-A, Karen Thurmer, Rev. Chad Slatter and Christ Episcopal Church, Charlotte Rich and the First United Methodist Women of Bluefield, the BC Business Office, and Lana Hartzog and Westminster Circle 3.
Internships were offered by Bluefield College, Saunders Staffing, the Tazewell County Public Library (Bluefield Branch), the Town of Bluefield, Virginia, the City of Bluefield, West Virginia, the Wade Center, and the W.I.S.E. Women's Center.


In the production of electronic equipment and semiconductors humidity can lead to electrostatic charge. For this reason, sensitive processing steps are being performed in cleanrooms and drying rooms. The mobile adsorption dryers of the TTR series are ideal for these high requirements during dehumidification.
At present the electronics and semiconductor industry is the sector putting the highest requirements on dehumidification in cleanrooms. For instance, a manufacturer of lithium-ion batteries asks for a relative humidity of only 2 per cent. A rather extreme value when compared with the average 10 per cent in the pharmaceutical industry or the 35 per cent in the automotive industry. To achieve such a high dehumidification perfectly adjustable, constantly working dehumidifiers are required.
The stationary and mobile adsorption dryers of the TTR series – by use of one of the three variations of the TTR functional principle – ensure a high dehumidification performance while simultaneously keeping the energy consumption low. Both mobile adsorption dryers marked with "D" for the Duoventic air volume regulation, TTR 400 D and TTR 500 D, provide maximum flexibility when adjusting the required amount of dry air. Owing to the innovative Duoventic air volume regulation both fans of the separate air circuits can be controlled independently via an infinitely variable electronic regulation. This enables an individual vernier adjustment of humidity level and volumetric flow of the required dry air and thus a precisely controlled percentage of relative humidity. TTR 400 D and TTR 500 D were designed for use in small cleanrooms or drying chambers.
Large drying rooms and cleanrooms can ideally be dehumidified by use of the stationary adsorption dryers serially numbered from TTR 800 to TTR 13500. They come equipped with the Monoventic control for the regulation of dry air. Another option is the Flowmatic control by use of which the volumetric flow of the dry air is kept constantly.
Reliable measurement technology and data loggers "made in Germany"
The electronics and semiconductor industry has to depend on extremely reliable measurement technology to keep a single-figure relative humidity value constant. Trotec, for instance, supplies the thermohygrometers T210 and T260. Furthermore, the data loggers of the MultiMeasure Professional series, DL200H or DL200X, manufactured in Germany, provide manifold opportunities for tamper-proof long-term measurements during dehumidification.
For the electronics and semiconductor industry the Trotec Group not only supplies dehumidifiers and measurement technology, but also technically and economically ideal solutions for climate conditioning. Our specialists in the industrial services team calculate all climate parameters and recommend the suitable devices. Moreover, we have mobile units on offer which can be used to test the planned dehumidification of your drying room in advance. This way, you can be sure that the proposed solution actually works.


text:
Formation Staff
Pontifical Status
According to Your Word
Review - Seanchas Ard Mhacha
Review - The Furrow
Collegium Hibernorum De Urbe
Creed of Love
Faith, Word and Culture
From Ráth Maoláin to Rome
Reflections at an Anniversary
The Irish College, Rome & its World
Ulster Earls & Baroque Europe
The Oliver Plunkett Union
The book presents the proceedings of a conference held at the Pontifical Irish College to honour Cardinal Desmond Connell on his eightieth birthday. The papers and responses celebrate Cardinal Connell as philosopher, theologian and pastor. Among the contributors are Cardinal William J Levada, Prefect for the Congregation for the Doctrine of the Faith, Dr Fran O'Rourke, University College Dublin, Dr Brendan Leahy, St Patrick's College Maynooth, and other internationally known philosophers, theologians, and members of the Roman Curia.
Monsignor Liam Bergin is a priest of the Diocese of Ossory and former Rector of the Pontifical Irish College, Rome. He lectured in dogmatic theology at the Pontifical Gregorian University, Rome. He is the author of O Propheticum Lavacrum – Baptism as Prophetic Act (Rome, 1998).

redpajama_set_name: RedPajamaCommonCrawl


text:
Cream-to-powder dermatological composition
A cream, comprising about 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, a surfactant, a hydrophilic and/or hydrophobic solvent, wherein, after application to a surface, dries to a uniform, visible, substantive, abrasion-resistant powder. The cream/powder composition is useful for a protective skin covering for preventing conditions such as bed sores, diaper rash, poison ivy or soothing uncomfortable feet, or as a delivery vehicle for a therapeutically-active dermatological agent, such as acne or fungal treatments, or as the delivery vehicle for treating other types of conditions, such a sore muscles, sore joints or microbial infections. Methods of making and using the cream also are included.
Rios, Luis A. (Penbroke Pines, FL, US)
Figueroa, Ramon (Hollywood, FL, US)
RIOS LUIS A.
FIGUEROA RAMON
A61K8/02; A61K8/19; A61K8/26; A61K8/39; A61K8/73; A61K8/86; A61K31/74; A61K47/02; A61K47/32; A61K47/36; A61P17/00; A61Q17/00; A61Q19/00; A61Q19/02; A61Q19/08; A61K9/70; (IPC1-7): A61K7/00
20020187161 H. pylori antigens December, 2002 Cripps et al.
20060239930 PROCESS FOR NEBULIZING AQUEOUS COMPOSITIONS CONTAINING HIGHLY CONCENTRATED INSULIN October, 2006 Lamche et al.
20030134790 Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer July, 2003 Langenfeld
20070026049 Method of increasing lean body mass and reducing body fat mass in infants February, 2007 Auestad et al.
20060173709 Bodywash additive business methods August, 2006 Traynor et al.
20020009466 ORAL VACCINE COMPOSITIONS January, 2002 Brayden
20050181042 Composition for oral or rectal administration August, 2005 Herslof
20050129642 Method of preventing undesired skin conditions beneath a woman's breasts June, 2005 Blanchard et al.
20060210499 Mild bleaching agents with increased lightening power September, 2006 Hoeffkes et al.
20050153001 Fenugreek seed extract to lower blood cholesterol July, 2005 Aburdeineh et al.
20030113303 Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances June, 2003 Schwartz
HUI, SAN MING R
TROUTMAN PEPPER HAMILTON SANDERS LLP (ATLANTA, GA, US)
1. A composition, comprising: a cream comprising 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, and a natural or synthetic film former, wherein the cream dries to a visible, abrasion-resistant powder when applied on the skin of an animal.
2. The composition of claim 1 further comprising a non-ionic, anionic or cationic surfactant, a hydrophilic solvent, a hydrophobic solvent, or combinations thereof.
3. The composition of claim 1 further comprising a therapeutically active agent such that an amount of the therapeutically active agent effective to treat or prevent the disorder is delivered to the animal having the disorder.
4. A composition, comprising: a cream comprising 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, a natural or synthetic film former and a therapeutically active agent such that an amount of the therapeutically active agent effective to treat or prevent the disorder is delivered to the animal having the disorder.
5. A method of preventing a disorder, comprising: applying to the skin of an animal in a location susceptible to the disorder, a cream comprising 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, and a natural or synthetic film former; and allowing the cream to dry to a visible, abrasion-resistant powder on the skin, wherein the visible, abrasion resistant powder protects the skin from the disorder.
6. The method of claim 5 wherein the cream further optionally comprises a non-ionic, anionic or cationic surfactant, a hydrophilic solvent, a hydrophobic solvent, or combinations thereof.
7. The method of claim 5 where in the disorder is chosen from the group comprising contact dermatitis, diaper rash, incidents of dibicutis ulcers and poison oak or ivy.
8. The method of claim 5 wherein the cream further comprises a therapeutically active agent such that an amount of the therapeutically active agent effective to treat or prevent the disorder is delivered to the animal having the disorder.
9. The method of claim 8 wherein the disorder is chosen from the group comprising muscle pain, joint pain, headache, migraine, bacterial infection, fungal infection, tinea capitis, tinea corporis, tinea cruris, tinea versicolor, viral infection, microbial infections, allergic reaction, actinic cheilitis, herpes, wounds, burns, warts, diaper rash, psoriasis, acne, seborrheic dermatitis, contact dermatitis, allergic dermatitis, hemorrhoids, wrinkles, insect bites, itching, sunburn, razor burn, eczema, psoriasis, chicken pox, rashes, blemishes.
10. The method of claim 8 wherein the disorder is inflammation.
11. The method of claim 10 wherein the therapeutic agent is an anti-inflammatory.
12. The method of claim 8 wherein the disorder is fungal itch.
13. The method of claim 12 wherein the therapeutic agent is miconazole nitrate.
14. The method of claim 8 wherein the disorder is chapped, dry skin associated with diabetes.
15. The method of claim 14 wherein the therapeutic agent is urea.
16. The method of claim 8 wherein the disorder is allergic itchy skin conditions.
17. The method of claim 16 wherein the therapeutic agent is diphenhydramine HCL.
18. The method of claim 8 wherein the disorder is muscle ache.
19. The method of claim 12 wherein the therapeutic agent is chosen from the group comprising capsaicin, methyl salicylate, or methyl nicotinate.
20. The method of claim 8 further comprising the step of monitoring the location and duration of application of the therapeutic agent by observing the visible, abrasive-resistant powder.
[0001] The present invention relates to a cream-to-powder dermatological composition that during initial application to the skin spreads as a conventional cream, gel, or ointment, and shortly after application dries to a uniform, visible, substantive abrasion-resistant powder. The cream-to-powder dermatological composition may be used as protection of skin against such disorders as bed sores, contact dermatitis, poison ivy and diaper rash. A therapeutically-active agent may also be added, wherein the cream/powder composition provides stationary dosing of an active agent.
[0002] A dermatological composition, with or without a therapeutically active agent, may be topically applied to the skin in a variety of formulations including a liquid, lotion, suspension, gel, balm, salve, ointment, emulsion, stick, spray, cream and powder. Cream formulations, because of their ease of application, are preferred topical formulations. However, cream formulations present problems including, but not limited to, greasiness, removal by contact, staining of clothing, evaporating from the skin, vanishing on the skin and drying to a scaly crust. Those cream formulations that evaporate from and vanish on the skin preclude visual monitoring of the maintenance of the applied cream formulation on the skin, and furthermore preclude from maintaining an active agent in a stationary position on the skin.
[0003] Powder formulations, because they are not greasy, do not stain clothing, temporarily do not evaporate from the skin or vanish from the skin and do not dry to a scaly crust, also are acceptable topical formulations. However, powder formulations present problems including, but not limited to, difficulty of application to a defined area, dispersion of volatile particles into the atmosphere and loss of the therapeutic activity on the skin, particularly if the case where therapeutic active is in a vehicle carrier are in an insoluble suspension. Therefore powder formulations preclude long-term visual monitoring of the maintenance of the applied powder formulation on the skin, and furthermore preclude from maintaining an active agent in a stationary position on the skin. For example, a commercial product (Dr. Scholl™) containing a miconazole nitrate in a spray powder is not substantive enough to deliver and keep the active agent in a stationary position as the powder is not sufficiently substantive and abrasive resistant.
[0004] Suspensions in general, be they in the form of a cream, gel, ointment, or powder, that act as carriers of insoluble active agents, tend to evaporate or migrate from the original application site, leaving insoluble active agents in a non-stationary position on the skin. Therefore, there is a need for a topical therapeutic composition that can be applied to a visually defined area and that remains visually defined for long periods of time on the skin. Furthermore there is a need for the same therapeutic composition to deliver therapeutically active agents in a stationary manner, particularly when deliver insoluble active agents. The topical therapeutic composition would ideally combine the ease of application of a cream, gel, or ointment with non-greasy, non-staining, non-evaporating, non-vanishing, non-volatile, and non-scaling properties.
[0005] This invention fulfills these needs by providing a hydrophilic, easy to apply spread-able cream composition (hereinafter, "cream") comprising about 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, and a natural of synthetic film former, such that, after application the cream dries to a uniform, visible, substantive, abrasion-resistant dry powder layer (hereinafter, "visible powder layer"). Optional ingredients also include a non-ionic, or anionic or cationic surfactant, a hydrophilic or hydrophobic solvent, and a therapeutically active agent (hereafter, "cream-active agent"). Methods of making the cream and the cream-active agent are included.
[0006] The cream-active agent of the present invention is particularly useful for dermatological applications and in particular for the treatment of dermatological and other disorders, and as a protective agent for the skin. The cream-active agent of the present invention, when applied to a defined area of a surface including, but not limited to, the skin, dries to a defined visible powder layer that remains on the surface until removed by a mild-surfactant and water, or by a strong surfactant and water, or by a mild dermatological cleansing lotion such as Cetaphyl Cleansing Lotion™ (Beiersdorf). The visible powder layer is non-greasy, non-staining, non-evaporating, non-vanishing, particulate non-volatile, non-scaling and enables visual identification and monitoring of the defined area to which the cream-active agent was applied. Furthermore, any active agent that is delivered by the cream-active agent is delivered in a stationary location within the skin surface. Moreover, the visible powder layer formed by the cream-active agent provides a vehicle from which an effective amount of the therapeutically active agent is delivered in a stationary location for immediate and/or during an extended time onto or into a surface.
[0007] Accordingly, it is the object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer.
[0008] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on a surface that that dries to a visible powder layer and that remains visible on the surface.
[0009] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and enables visual identification of the area of application for the time it remains on the skin.
[0010] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on a surface that dries to a visible powder layer and that remains visible on the surface until removed with a mild or strong surfactant or by a mild dermatological cleansing lotion such as Cetaphyl Cleansing Lotion™ (Beiersdorf).
[0011] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on a surface that dries to a visible powder layer and that remains visible on the surface until removed with a strong surfactant, for use with uncooperative patients, such as children, pets, livestock or difficult adult patients.
[0012] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer that acts as a carrier for delivering stable therapeutically active agents.
[0013] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer that can act as a carrier of anionic, cationic, amphoteric, and non-ionic therapeutically active agents.
[0014] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application as a therapeutic treatment on the skin of an animal, including a human, that dries to a visible powder layer and that enables visual monitoring of therapeutic time of action on the area of application for the time it remains on the skin.
[0015] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application as a therapeutic treatment on the skin of an animal, including a human, that dries to a visible powder layer and will not cause irritation on the skin for the time it remains on the skin.
[0016] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer that can act as a carrier for delivering a therapeutically active agents to a stationary location of the skin.
[0017] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables treatment of skin related disorders.
[0018] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that is applied to small, defined areas of the skin.
[0019] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that is applied to large defined areas of the skin.
[0020] Another object of the present invention to invention is to provide an easy to apply spread-able cream-active agent for application on a surface that dries to a visible powder layer and that delivers therapeutically active agents onto the skin.
[0021] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human that dries to a visible powder layer and that delivers the therapeutically active agents into the skin.
[0022] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables simple, safe and non-invasive administration of therapeutically active agents onto the skin.
[0023] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables simple, safe and non-invasive administration of therapeutically active agents into skin.
[0024] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and enables delivery of therapeutically active agents onto the skin immediately.
[0025] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and enables delivery of therapeutically active agents into the skin immediately.
[0026] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables delivery of therapeutically active agent onto the skin during an extended time.
[0027] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables delivery of therapeutically active agents into the skin during an extended time.
[0028] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that has skin-protection properties.
[0029] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that promotes wound healing.
[0030] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that promotes relief of inflammatory skin conditions.
[0031] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes analgesic effects.
[0032] Another object of the present invention is to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that enables simple, safe administration of therapeutically active agents into skin to deliver vasodialator agents to increase microcirculation to prevent or relieve incidents of dibicutis ulcers from forming in bed-ridden patients.
[0033] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes relief of allergic itchy skin conditions.
[0034] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes anti-microbial effects.
[0035] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes keratolytic effects.
[0036] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes skin lightning effects for hyper-pigmentation disorders.
[0037] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promote relief for excessive sebaceous gland secretion.
[0038] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and promotes protection against fecal microorganisms.
[0039] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of an animal, including a human, that dries to a visible powder layer and that acts as skin protective or prophylactic layer against a covering.
[0040] Another object of the present invention to invention to provide an easy to apply spread-able cream-active for application on the skin of the hands that dries to a visible powder layer and that acts as a skin protective or prophylactic layer against induced contact dermatitis.
[0041] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of the hands that dries to a visible powder layer and that acts as a skin protective or prophylactic layer against gloves.
[0042] Another object of the present invention to invention to provide an easy to apply spread-able cream-active for application on the skin of the hands that dries to a visible powder layer and that acts as a skin protective or prophylactic layer against glove induced contact dermatitis.
[0043] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of the hands that dries to a visible powder layer and that acts as a visual indicator of glove perforation or breakage.
[0044] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of the hands that dries to a visible powder layer and that provides protection against microbial contamination resulting from glove perforation or breakage.
[0045] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin that dries to a visible powder layer and that provides protection against microbial contamination.
[0046] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of the hands that dries to a visible powder layer and that provides protection against microbial contamination and provides visual warning against blood contamination resulting from glove perforation or breakage.
[0047] Another object of the present invention to invention to provide an easy to apply spread-able cream-active agent for application on the skin of the hands that dries to a visible powder layer and that provides microbial contamination and provides visual warning against contamination resulting from glove perforation or breakage by incorporating color indicators into the cream active agent.
[0048] These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.
[0049] The present invention provides a cream comprising about 5 to 60% of a non-swelling clay, a swelling clay, a natural gum, a non-ionic surfactant and a hydrophilic and/or hydrophobic solvent, wherein, after application to a surface, the cream dries to a visible powder layer. Further, the present invention provides a cream-active agent comprising about 5 to 60% of a non-swelling clay, a swelling clay, a natural or synthetic gum, a non-ionic surfactant, a natural or synthetic film former, a hydrophilic solvent, a hydrophobic solvent, or combinations thereof, and a therapeutically active agent, wherein, after application to a surface, the cream dries to visible powder layer from which an effective amount of the active agent is delivered onto or into the surface immediately and/or over an extended time.
[0050] As used herein, the term "active agent" includes any natural or synthetic agent, any pharmaceutical agent that treats the disorder for which it is applied.
[0051] As used herein, the term "pharmaceutical" includes any natural or synthetic agent approved by a regulatory agency of a country or a state government for the treatment of a disorder or listed in the U.S. Pharmacopoeia (USP) or other generally recognized pharmacopoeia for use in an animal, including a human.
[0052] As used herein, the term "stable therapeutically-active agents" includes any natural or synthetic agent approved by a regulatory agency of a country or a state government or listed in the U.S. Pharmacopoeia (USP) or other generally recognized pharmacopoeia for use in an animal, including a human, that when used in a composition, is stable under pharmaceutically accepted standards of accelerated storage conditions.
[0053] As used herein, the word "substantive" is defined as a property of the dried phase of the dermatological cream of the present invention, the powder, wherein the powder can not be rubbed off by daily abrasive conditions, such as rubbing against clothing, wearing shoes and socks all day, or attempting to rub off with the hands. The cream-active agent of the present invention is substantive, wherein the cream-active agent is not easily removable unless when removed with at least one removing agent, such as with a surfactant and water, preferably a mild surfactant and water. It is to be understood that while a small amount of the composition of the invention may be rubbed or scratched off, a majority of the composition will remain at the location of application until it is washed off with water and the removing agent.
[0054] As used herein, the word "skin" includes the epidermis, dermis, sebaceous glands and mucus membranes of an animal, including a human. Mucous membranes include, but are not limited to, vaginal mucosa to promote moisture absorption and reduce high moisture environment that is conducive to yeast viability.
[0055] As used herein, the term "hydrophobic solvent" includes any solvent that repels water molecules.
[0056] As used herein, the term "hydrophilic solvent" includes any solvent that repels lipid molecules.
[0057] As used herein, the term "extended time" refers to a period of time that allows at least a twofold reduction in dosing frequency of an active agent as compared to the active agent presented in a conventional dosage form. (United States Pharmcopeia- USP XXI, Preface, pg. XLIII).
[0058] In contrast to prior art methods, wherein either a cream formulation or a powder formulation is applied on a surface, the present invention provides a novel composition and method, wherein a cream, applied on a surface, dries to a visible powder layer. After application on the surface, the cream dries to the visible powder layer preferably within about 10 seconds to 30 minutes, more preferably within about 20 seconds to 15 minutes and most preferably within about 30 seconds to 5 minutes. The visible powder layer acts as an active agent carrier, a moisture barrier, a protective film and a visual indicator of product site of application. For example, an appropriate amount of cream-active agent, applied to the buttocks of a baby, dries to a visible powder layer that provides an active agent delivery carrier, a moisture barrier, a protective film and a visual marker of the area of cream application. Moreover, as the visible powder layer is non-greasy and non-staining and is not displaced by movement, contact or abrasion, it can be covered with a diaper without concern that the composition will be rubbed off or absorbed into the diaper.
[0059] Also, in contrast to prior art methods, wherein an active agent is applied on a surface in either a cream formulation or in a powder formulation, the present invention provides a novel composition and method, wherein a cream-active agent is applied on a surface and dries to a visible powder layer. The active agent is chemically or physically incorporated into the cream-active vehicle in a soluble or as an insoluble suspension, or a combination of both, such that, as the cream dries to a visible powder layer, the active agent remains in stationary contact with the surface for a time sufficient to be effective. Active agents for use in the cream-active agent formulation include therapeutically active agents that are contained within the visible powder layer in a dry or wet state and are covered or surrounded by the visible powder layer. For use, an amount of a cream-active agent, containing an effective amount of the active agent, is applied on a defined small or large area of the skin, one or more times until a desired result is obtained. The visible powder layer is not displaced from the surface by movement, contact or abrasion.
[0060] In one embodiment, the present invention is useful for treatment of dermatological conditions, wherein a cream-pharmaceutical agent is applied on a defined area of skin and dries to a visible powder layer. The pharmaceutical active agent is either chemically or physically incorporated in the cream in a soluble or as an insoluble suspension, or a combination of both, such that, as the cream dries to a visible powder layer, the pharmaceutical active agent is maintained in stationary contact with the surface for a time sufficient to be effective. For use, an amount of a cream-pharmaceutical agent, containing an effective amount of the pharmaceutical agent, is applied on a defined area of skin one or more times until a desired result is obtained. Moreover, as the visible powder layer is non-greasy and non-staining and is not displaced by movement, contact or abrasion, it can be covered with clothing.
[0061] In an example to treat acne, a cream containing an effective amount of an agent for treating acne, such as the pharmaceutical agent salicylic acid, is applied on the area to be treated, such as the face, chest or back. The cream dries to a visible powder layer that is non-greasy, non-staining, abrasion resistant and that enables visual identification of the area of application. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing. The cream may be used overnight on all areas, including the face, without rubbing off on bedclothes or pillows. Other types of acne treating agents are well-known in the art and are included in this invention. The cream/powder composition can be removed using a mild surfactant and water.
[0062] In an example to treat rectal itching, a cream containing an effective amount of an analgesic, such as Pramoxine HCL, is applied to the rectal area and dries to a visible powder layer that is non-greasy, non-staining, abrasion resistant and moisture absorbing. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing and overnight without rubbing off on bedclothes. Other types of analgesic agents for treating hemorrhoids and rectal itching are well-known in the art and are included in this invention. The cream/powder composition can be removed using a mild surfactant and water. The cream-analgesic offers an advantage over currently marketed products such as ANUSOL® and PREPARATION H® that are petrolatum based ointments and, therefore are greasy, staining, non-moisture absorbing and do not offer a stationary localization on the skin of the active agent in suspension.
[0063] In an example to treat poison ivy or poison oak, a cream containing an effective amount of Hydrocortisone, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing. The cream may be used overnight on all areas, including the face, without rubbing off on bedclothes or pillows. Other types of agents for treating poison ivy or poison oak are well-known in the art and are included in this invention. The cream-hydrocortisone/powder can be removed using a mild surfactant and water. The cream-hydrocortisone/powder offers an advantage over currently marketed hydrocortisone ointments products that are messy, staining, that cannot easily be covered by clothing, do not offer a stationary localization on the skin for the active agent in suspension.
[0064] In an example to treat allergic itchy skin conditions, a cream containing an effective amount of Diphenhydramine HCL, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing. The cream may be used overnight on all areas, including the face, without rubbing off on bedclothes or pillows. Other types of agents for treating allergic itchy skin conditions are well-known in the art and are included in this invention. The cream-Diphenhydramine/powder offers an advantage over currently marketed products such as BENADRYL LOTION™ by providing long lasting skin protective effects and visual monitoring of site of application. The cream-Diphenhydramine/powder can be removed using a mild surfactant and water.
[0065] In an example to treat itchy skin conditions associated with fungal conditions such as Athlete's Foot, a cream containing an effective amount of miconazole nitrate, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing and may be used overnight without rubbing off on bedclothes. Other types of fungal treating agents are well-known in the art and are included in this invention. The cream-anti-fungal/powder can be removed using a mild surfactant and water. The cream-antifungal/powder offers an advantage over currently marketed Miconazole powder products in that it is soothing, abrasive resistant, and long lasting.
[0066] In an example to treat chapped, dry skin conditions associated with diabetes, a cream containing an effective amount of urea, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing. The cream may be used overnight on all areas, including the face, without rubbing off on bedclothes or pillows. Other types of agents for treating chapped, dry skin are well-known in the art and are included in this invention. The cream-urea/powder can be removed using a mild surfactant and water. The cream-urea/powder offers an advantage over currently marketed urea cream and ointment products in that it is soothing, abrasive resistant, moisture absorbing, and long lasting.
[0067] In another embodiment, the present invention is useful for the protection from dermatological conditions, wherein the cream without a pharmaceutical agent is applied on a defined area of skin and dries to a visible powder layer. For use, an amount of a cream is applied on a defined area of skin to protect against possible conditions, such as contact dermatitis, allergic reaction, bed sores from laying in one position for too long, irritated skin from urinary incontinence or diaper rash. Moreover, as the visible powder layer is non-greasy and non-staining and is not displaced by movement, contact or abrasion, it can be covered with clothing.
[0068] In an example to protect against diaper rash, an effective amount of the cream for protecting the skin from the irritants found in urine or fecal material is applied on the area to the diaper area. The cream dries to a visible powder layer that is non-greasy, non-staining, abrasion resistant and that enables visual identification of the area of application. After the cream dries to a powder, the cream may be used without rubbing off onto the diaper or being absorbed by the diaper. The cream/powder composition can be removed using a mild surfactant and water.
[0069] In an example to protect against bed sores, an effective amount of the cream for protecting the skin from bed sore ulcers is applied on the area to the diaper area. The cream dries to a visible powder layer that is non-greasy, non-staining, abrasion resistant and that enables visual identification of the area of application. After the cream dries to a powder, the powder will not rub off onto or be absorbed by the bedclothes. The cream/powder composition can be removed using a mild surfactant and water. Alternatively, the cream may have a vasodilator added as a therapeutic agent, to assist in the prevention of bed sore ulcers.
[0070] In another embodiment, the present invention is useful for the delivery of therapeutics through the skin for the treatment of conditions other than dermatological, wherein a cream-pharmaceutical agent is applied on a defined area of skin and dries to a visible powder layer. The pharmaceutical active agent is either chemically or physically incorporated in the cream in a soluble or as an insoluble suspension, or a combination of both, such that, as the cream dries to a visible powder layer, the pharmaceutical active agent is maintained in stationary contact with the surface for a time sufficient to be effective. For use, an amount of a cream-pharmaceutical agent, containing an effective amount of the pharmaceutical agent, is applied on a defined area of skin one or more times until a desired result is obtained. Moreover, as the visible powder layer is non-greasy and non-staining and is not displaced by movement, contact or abrasion, it can be covered with clothing.
[0071] In an example to soothe muscle aches, a cream containing an effective amount of an agent for treating muscle aches, such as the pharmaceutical agents of capsaicin, methyl salicylate, or methyl nicotinate, is applied on the area to be treated, such as the shoulders, chest or back. The cream dries to a visible powder layer that is non-greasy, non-staining, abrasion resistant and that enables visual identification of the area of application. After the cream dries to a powder, the cream may be used inconspicuously during the day under clothing without rubbing off onto the clothing or staining the clothing. The cream may also be used overnight without rubbing off on bedclothes or pillows. Other types of pain treating agents are well-known in the art and are included in this invention. The cream/powder composition can be removed using a mild surfactant and water.
[0072] In an example, to treat psoriatic skin conditions, a cream containing an effective amount of anthralin, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. The cream-anthralin offers an advantage over currently marketed products such as DITHRANOL™ by providing long lasting skin protective effects and visual monitoring of site of application. This is especially important as anthralin may irritate the skin, and visual monitoring will help with removal of the therapeutic when treatment is complete. The cream-base of the cream-anthralin composition also slows down the delivery of the sometimes irritating therapeutic. The cream-anthralin can be removed using a dermatological lotion like Cetaphyl Lotion™ or mild surfactant and water on the alkaline side of pH.
[0073] In an example, to treat hyper-pigmentation conditions of the skin associated dark spots and age spots related to extensive exposure to sunlight, a cream containing an effective amount of hydroquinone, is applied to the affected area and dries to a visible powder layer that is non-greasy, non-staining, non-scaly and that can easily be covered by clothing. The cream-hydroquinone can be removed using a mild surfactant and water. The cream-hydroquinone offers an advantage over currently marketed skin lightning products in that it is soothing, abrasive resistant, long lasting and visible monitors site of application.
[0074] The cream component of the present invention comprises one or more non-swelling clays, swelling clays, natural gums, non-ionic surfactants, hydrophilic and/or hydrophobic solvents, each of which is toxicologically, pharmaceutically and generally regarded as safe (GRAS) according to U.S. Federal Food and Drug Regulation Standards. If an active agent is part of the composition, the active agent is a pharmaceutical agent.
[0075] The compounds listed below are those of standard use in the art. The examples provided do not limit the types of compounds to be used in the invention, but are merely illustrative. Other compounds of standard use and non-standard use in the art may also be used.
[0076] Non-swelling clays include, but are not limited to, kaolin. Swelling clays include, but are not limited to, montmorillonite clays. Montmorillonite clays include, but are not limited to, magnesium aluminum silicate, bentonite, hectorite, or surface reactive montmorillonite clays including, but not limited to, stearalkonium hectorites. Natural gums include, but are not limited to, xanthan gum, guar gum, gum arabic, carrageenan and alginates. Alginates include, but are not limited to, alginic acid and sodium alginate. Synthetic gums include but are not limited to acrylic polymers. Non-ionic surfactants include, but are not limited to, stearates, palmitostearates, glycerides, sorbitan esters, polyoxyethylene ethers, polyoxyethylene glycol esters, C20-C24 glyceryls and emulsifying waxes. Stearates include those with melting ranges between about 33.0° and 97.5° C. such as, but not limited to, polyethylene-6 stearate, polyethylene-35 stearate, glyceryl stearate, glycol stearate and polyglycol stearate (average MW ≧300). Palmitosterates include those with melting ranges between about 26.5° and 62.0° C. such as, but not limited to, glyceryl palmitostearates, polyglycol (average MW ≧300), palmitostearates and propylene glycol palmitostearates. Glycerides include those with melting ranges between about 29.0° to 70.0° C. such as, but not limited to, saturated polyclycolised glycerides (GELUCIRE, Gattefosse Corp, Westwood, N.J.) with melting ranges between about and 31.0° to 45.0° C., C12-C18 glycerides, hemisynthetic glycerides and caproyl/capric glycerides. Sorbitan esters include those with melting points ≧25.5° C. such as, but not limited to, sorbitan palmitate, sorbitan stearate and sorbitan tristearate. Polyoxyethylene ethers include those with melting points ≧26.5° C. such as, but are not limited to, laureth-12, ceteth-2, steareth-2, oleth-20, ceteareth-4, trideceth-12, and PEG-40 hydrogenated castor oil. Polyoxyethylene glycol esters include those with melting points ≧26.5° C. such as, but not limited to, PEG-8 stearate, PEG-100 stearate, PEG-8 distearate, and PEG-150 distearate. C20-C24 glyceryls include those with melting points ≧26.5° C. such as, but not limited to, glyceryl behenate and glyceryl tribehenate. Emulsifying waxes include those with melting points ≧26.5° C. such as, but not limited to, emulsifying wax NF, cetearyl alcohol and ceteareth-20, stearyl alcohol and ceteareth-20, cetearyl alcohol and ceteth-20. Hydrophilic solvents include, but are not limited to, water, glycerin, propylene glycol and polyethylene glycol (average MW<600 Da). Natural or Synthetic film formers include but are not limited to chitosan, albumin, hyaluronic acid and poly vinyl pyrilidone (PVP). Hydrophobic solvents include, but not limited to hydrocarbons such as mineral oil, esters such as isopropyl myristate, and silicone ingredients such as dimethicone.
[0077] By percent weight, the cream-active of the present invention comprises non-swelling clay preferably at about 5 to 60%, more preferably at about 10 to 50% and most preferably at about 15 to 40%; swelling clay preferably at about 0.2 to 20%, more preferably at about 0.5 to 10% and most preferably at about 1 to 5%; non-ionic surfactant preferably at about 0.5 to 30%, more preferably at about 1 to 20% and most preferably at about 2 to 15%; natural or synthetic gum preferably at about 0.01 to 5%, more preferably at about 0.02 to 2% and most preferably at about 0.05 to 1%; a natural or synthetic film former at about 0.01 to 1%, more preferably at about 0.02 to 0.5%, and most preferably at about 0.1 to 0.25%; a hydrophilic and/or hydrophobic solvent to 0.1 to 20%, and a therapeutically-active agent at about 0.001 to 50%. The viscosity of the cream is preferably between about 10,000 and 15,000,000 centipoise, more preferably between about 50,000 and 12,500,000 centipoise and most preferably between about 100,000 and 10,000,000 centipoise.
[0078] Optional ingredients for use in the cream of the present invention include, but are not limited to, water insoluble powders, preservatives and humectants. Water insoluble powders include, but are not limited to, talc, starch, starch derivatives, polymers, zinc oxide, titanium dioxide, silicon dioxide, metal stearates, mica and combinations thereof. Metal stearates include, but are not limited to, magnesium stearate and zinc stearate. Preservatives include, but are not limited to, benzyl alcohol, boric acid, chloroxylenol, dehydroacetic acid, orthophenylphenol, quatemium-15, ethanol, diazolidinyl urea, imidazolidinyl urea, hydantion, benzethonium chloride, potassium sorbate, sodium benzoate, phenoxyethanol, phenylethyl alcohol, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, sorbic acid, glutaraldehyde and combinations thereof. Humectants include, but are not limited to, glycerin, hexylene glycol, propylene glycol, sorbitol, fructose, glucose, lactose, polyammio sugar condensate, hydrogenated starch hydrolysate, acetamide DEA, glycereth-7, honey, methyl gluceth-10, PCA, sodium lactate, saccharide hydrolysate, xylitol, botanical extracts and combinations thereof.
[0079] Other optional ingredients include, but are not limited to, pigments, emollients, acidifying agents, propellants, alcohols, alkalinizing agents, antifoaming agents, antioxidants, buffering agents, suspending agents, chelating agents, coating agents, complexing agents, coloring agents, desiccants, flavors, perfumes, plasticizers, solvents, sorbents, penetration enhancers, stiffening agents, tonicity agents, thickening agents, viscosity increasing agents, sweetening agents, oils, solid carriers, water repelling agents, wetting agents, solubilizing agents, natural polymers, synthetic polymers and combinations thereof. Natural polymers and synthetic polymers include, but are not limited to, acrylic copolymers, methacrylates, hydroxypropyl cellulose, hydroxyethylcellulose and hydroxypropylmethyl cellulose.
[0080] Active agents for use in the cream-active agent include, but are not limited to, natural agents, synthetic agents, chemical agents, pharmaceutical agents and combinations thereof that are completely soluble, partially soluble or insoluble in aqueous solution. Pharmaceutical agents include, but are not limited to, analgesics, anesthetics, antibiotics, anti-infectives, antimicrobials, anti-inflammatories, anti-neoplastics, antirheumatics, antivirals, antifungals, anticomediforms (acne), antihistamines, antialopecias, antipruritics, antipsoriatics antiseborrheics, anti-herpetiformes, enzymes, keratolitics, steroids, local anesthetics, antiseptics disinfectants, pigmentors depigmentors, hair growth stimulants, vasodilators, rubefacients, protectants and sunscreens. Pharmaceutical agents include, but are not limited to itraconazole, miconazole, fluconazole, ketoconazole, tetracaine, lidocaine, mepivicaine, phenol, pramoxine, prilocaine, procaine, benzoyl peroxide, resorcinol, retinoic acid, histamine, poison ivy extract, beclomethasone, dexamethasone, minoxidil, neomlycin, tolnaftate, undecylenic acid, salicylic acid, nimesulide, camphor, menthol, anthralin, pyrithione, selenium sulfide, alcohols, chlorbexidine, bismuth subgallate, sulfur, triclosan, hydrogen peroxide, chlorxylenol, hexachlorophene, chlorhexidine and chlorhexidine salts, benzethonium chloride, silver nitrate, boric acid, acyclovir, hydroquinone, allantoin, calamine, titanium dioxide, zinc, oxide, dimethicone, PABA, oxybenzone dithranol, salicylates, griseofulvin, vitamins A, vitamin D, vitamin E, proteolytic enzymes, mucolytic enzymes, corticosteroids, hydrocortisone sunscreens, protectants, aloe, capsaicin, chamomile, panthenol, fluticazone diproprionate, coal tar, alpha hydroxy acids, beta hydroxy acids, ammonium lactate, calcipotriene, 5-fluorouracil.
[0081] Optional color indicators for use in the cream-active agent include any color indicator substance, not limited to any pigment, pH indicator, or gram negative and gram positive color indicators such as crystal violet, Iodine, sefranin and combinations thereof.
[0082] In an example, a cream-active agent is applied on a defined area of skin and, dries to a visible powder from which the active agent is delivered onto the epidermal layer of the skin. In another example, a cream-active agent is applied on a defined area of skin and dries to a visible powder layer from which the active agent is delivered through the epidermal layer into the dermal layer of the skin.
[0083] The cream-active agent is useful for the prevention and treatment of diseases and disorders of the skin of an animal, including a human, and, more importantly, for the prevention and treatment of diseases and disorders affecting all parts of an animal, including a human. Such diseases and disorders include, but are not limited to, muscle pain, joint pain, headache, migraine, bacterial infection, fungal infection, tinea capitis, tinea corporis, tinea cruris, tinea versicolor, viral infection, microbial infections, allergic reaction, actinic cheilitis, herpes, wounds, burns, warts, diaper rash, psoriasis, acne, seborrheic dermatitis, contact dermatitis, allergic dermatitis, hemorrhoids, wrinkles, insect bites, itching, sunburn, razor burn, eczema, psoriasis, chicken pox, rashes, blemishes and other diseases and disorders.
[0084] The cream-active agent used, the number of applications and the schedule of application will depend on the disease or disorder being prevented or treated, the severity of the disease or disorder, the location of the disease or disorder and other clinical factors such as the size and physical condition of the recipient and can be determined by the medical practitioner using standard clinical techniques and without undue experimentation. The cream-active agent is applied to a defined surface area preferably 1 to 10 times per 24 hours, more preferably 3 to 6 times per 24 hours and most preferably 2 to 5 times per 24 hours. The amount of cream applied is preferably between about 1 and 100 mg/cm2, more preferably between about 10 and 90 mg/cm2 and most preferably between about 20 and 70 mg/cm2. The amount of active agent in the cream depends on the condition to be treated, individually characteristics of the patient and the strength of the active agent. Guidelines for dosage are those that are standard in the art. Generally, the amount of active agent in the cream is preferably from about 0.001 to 50%, more preferably from about 0.01 to 30%, and most preferably from about 0.1 to 10%. The amount of active agent per application is preferably between about 0.05 and 500 mg, more preferably between about 0.1 and 300 mg and most preferably between about 0.5 and 100 mg. However, variations may be required based on individual factors.
[0085] This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.
[0086] Preparation of a Cream-Active I—Product for Athlete's Foot
[0087] In an embodiment of the present invention, a cream-active agent containing the pharmaceutical agent miconazole nitrate USP was prepared as follows. NF is the National Formulary. 1
INGREDIENT % w/w
Xanthum gum NF 0.2
Magnesium aluminum silicate NF 3.0
Kaolin USP 29.0
Talc USP 6.0
Purified water USP q.s. to 100%
PEG-6 stearate & PEG-32 stearate 5.0
Ethoxydiglycol 4.0
Sorbic Acid NF 0.1
PVP 0.02
Purified water USP 1.0
Imidurea NF 0.3
Miconazole nitrate USP 2.0
[0088] 1. Xanthum gum NF (KETROL F, Monsanto, Chicago, Ill.) and the magnesium aluminum silicate NF (VEEGUM ULTRA, RT Vanderbilt, Norwalk, Conn.) were dry blended in a suitably sized blender.
[0089] 2. Purified water USP was charged into a suitably sized jacketed stainless steel kettle equipped with a Lightnin type mixer (VWR Scientific, Pittsburgh, Pa.) and a double-motion impeller and was heated to between 73° and 77° C. During heating, the purified water USP was mixed vigorously with the Lightnin type mixer.
[0090] 3. The step 1 mixture was dispersed into the purified water USP by sprinkling it into the vortex of the mixing water and mixing was continued for 60 to 75 minutes, followed by mixing with a double motion impeller.
[0091] 4. While maintaining temperature and mixing conditions, the following ingredients were added in order: kaolin USP (VANCLAY, RT Vanderbilt, Norwalk, Conn.), talc USP (MIRAGE 500, Ultra, Red Bank, N.J.), PEG-6 stearate and PEG-32 Stearate (TEFOSSE 1500, Gattefosse Westwood, N.J.), glycerin USP (Jeen International, Little Falls, N.J.), sorbic acid NF (Eastman, Kingsport Tenn.) and potassium sorbate NV (Jeep International, Little Falls, N.J.).
[0092] 5. After thorough mixing of all ingredients, the mixture (step 4) was cooled to 50° C. with constant mixing.
[0093] 6. The imidurea NF (GERMALL 115, ISP, Wayne, N.J.) and purified water USP of Part B were mixed together and were added to the mixture of step 5 with constant mixing.
[0094] 7. The miconazole nitrate USP (Zetapharm, New York, N.Y.) of Part C was slowly mixed into the step 6 mixture, and mixing was continued until a uniform pasty cream was obtained.
[0095] 8. The mixture was cooled to below 40° C. with continued mixing until a uniform pasty cream is obtained.
[0096] The cream is packaged into individual aluminum tubes of between 4 and 60 mgs using methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions.
[0097] The viscosity of the cream-miconazole nitrate was 1,200,000 cps as tested by Brookfield viscometer Model LVT, Spindle 7, 0.05 RPM.
[0098] The cream-active agent is packaged in aluminum tubes of between 4 and 60 grams using methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The product delivers miconazole nitrate onto the skin for extended periods of time.
[0099] Stability of Cream-Active Agent I
[0100] Example 1 cream-miconazole nitrate was packaged in 15 g aluminum tubes and stored at 40° C. for 3 months. The stability of Example 1 cream-miconazole nitrate was assayed a 0 (initial) 1, 2 and 3 month intervals using the stability assay for miconazole nitrate cream described in the United States Phairmacopeia XXII at page 898. The results are shown in Table 1. 2
Stability of Example 1 cream-miconazole nitrate
1- 2- 3-
TEST INITIAL MONTH MONTHS MONTHS
ASSAY(% of Initial) 100 99 100 105
Appearance *UC UC UC
*unchanged from initial appearance of a light-brown pasty cream.
[0101] These data demonstrate that the miconazole nitrate in the cream-miconazole nitrate of Example 2 remained stable over 3 months at 40° C. and that the pH of the cream-miconazole nitrate remained stable over the 3 month period. As defined in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa. 1990, p. 1504), a product needs to retain retain ≧90% of its labeled value as the minimal acceptable level of stability. A product that retains ≧90% of its labeled value over 3 months at accelerated conditions (40° C.) enables a manufacturer to claim 2 years shelf life at room temperature (25° C.) (FDA Guidance for Industry: Stability testing of Drug Substances and Drug Products).
[0102] Preparation of Cream-Active Agent II—Product for Rectal Itch
[0103] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent pramoxine hydrochloride USP was prepared as follows. 3
Methylparaben NF 0.3
Propylparaben NF 0.15
Imidurea NF 0.15
Pramoxine hydrochloride USP 1.0
[0104] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The pramoxine hydrochloride USP (Abbot, North Chicago, Ill.) of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 2 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-pramoxine hydrochloride was 640,000 cps as tested by Brookfield viscorneter, Model LVT, Spindle 7, 0.05 RPM.
[0105] The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The product delivers Pramoxine HCL into the skin for extended periods of time.
[0106] Stability of Cream-Active Agent II
[0107] Example 3 cream-pramoxine hydrochloride was packaged in 15 g aluminum tubes and stored at 40° C. during the 3 months. The stability of Example 3 cream-pramoxine hydrochloride was assayed a 0 (initial) 1, 2 and 3 month intervals using the stability assay for pramoxine hydrochloride cream described in the United States Pharmacopoeia XXII at page 1122. The results are shown in Table 2. 4
Stability of Example 4 cream-pramoxine hydrochloride
ASSAY (% of initial) 1.12% 1.15% 1.01% 1.00%
[0108] These data demonstrate that the pramoxine hydrochloride in Example 4 cream-pramoxine hydrochloride remained stable over 3 months at 40° C. and that the pH of the cream-pramoxine hydrochloride remained stable over the 3 month period. The pH of the cream-miconazole nitrate remained stable over the 3 month period.
[0109] Preparation of Cream-Active Agent III—Product for Allergic Itch Skin Conditions
[0110] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Diphenhydramine Hydrochloride was prepared as follows. 5
Polowax NF 5.0
Glycerin USP 4.0
Chitosan 0.2
Diphenhydramione hydrochloride USP 1.0
[0111] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Diphenhydramine hydrochloride USP (Sigma) of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 2 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-Diophenhydramine hydrochloride was 840,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM.
[0112] The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions.
[0113] Preparation of Cream-Active Agent IV—Product for Diabetic Foot
[0114] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Urea USP was prepared as follows. 6
Purified water USP q.s to 100%
Pentalene Glycol 4.0
Isopropyl Myristate NF 1.0
Hyaluaronic acid 0.02
Urea USP 20.0
[0115] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Urea USP (EM Industries) of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-urea was 700,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM.
[0116] The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The product is tested on 100 subjects under a Repeat Insult Patch Test (RIPT) and demonstrate no significant clinical indication to cause irritation.
[0117] Preparation of Cream-Active Agent V—Skin Protection Product Against Contact Dermatitis
[0118] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Benzothonium Chloride was prepared as follows. 7
Albumin 0.02
Benzothonium Chloride 0.2
[0119] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Benzothonium Chloirde of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-Benzothonium was 700,000 cps as tested by field viscometer, Model LVT, Spindle 7, 0.05 RPM.
[0120] The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. There is no incompatibility between the base and the cationic active agent.
[0121] Preparation of Cream-Active Agent VI—Anti-Microbial Product for under Latex Glove Use
[0122] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Triclosan was prepared as follows. 8
PVP 0.2
Triclosan USP 1.0
[0123] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Triclosan USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-triclosan was 1,200,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM.
[0125] Preparation of Cream-Active Agent VII—Acne Scars—Physician TCA Skin Peel Mask
[0126] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Trichloracetic acid was prepared as follows. 9
Ethoxidiglycol 7.0
Bisabolol 0.2
Trichloracetic acid USP 1.0
[0127] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Triclosan USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-triclosan was 900,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM. The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The active agent is delivered into the skin. Product is used for 10-20 minutes and removed by rinsing with water and mild surfactant.
[0128] Preparation of Cream-Active Agent VIII—Psoriasis—Anthralin Product
[0129] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Anthralin was prepared as follows. 10
Propylene Glycol USP 4.0
Anthralin USP 1.0
[0130] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Anthralin USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-anthralin was 900,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM. The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The active agent is delivered onto the skin. Product is used for 10-20 minutes and removed by rinsing with water and mild alkaline pH surfactant.
[0131] Preparation of Cream-Active Agent IX—Poison Ivy—Hydrocortisone Product
[0132] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Hydrocortisone was prepared as follows. 11
Hydrocortisone USP 1.0
[0133] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Hydrocortisone USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-hydrocortisone was 1,100,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM. The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The active agent is delivered onto the skin. Product is used for long periods of time for extended release of hydrocortisone onto skin.
[0134] Preparation of Cream-Active Agent X—Skin Lightning—Hydroquinoone Product
[0135] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Hydroquinone was prepared as follows. 12
1,3 Butylene Glycol 3.0
Sodium Bisulfite USP 0.6
Hydroquinone USP 2.0
[0136] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Hydroquinone USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-hydroquinone was 1,000,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM. The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The active agent is delivered onto the skin. Product is used for long periods of time for extended release of hydroquinone onto skin.
[0137] Preparation of Cream-Active Agent XI—Microcirculation Product for Debicutis Ulcers
[0138] In an embodiment of the present invention, a cream-active agent containing pharmaceutical agent Methyl Nicotinate was prepared as follows. 13
Alginate gum 0.5
Methyl Nicotinate USP 0.2
[0139] Part A and Part B ingredients were mixed together as in steps 1-6 of Example 1. The Methyl Nicotinate USP of Part C was slowly mixed into the step 6 mixtures as in step 7 of Example 1 and mixing was continued until a uniform pasty cream was obtained. The viscosity of the cream-Nicotinate was 700,000 cps as tested by Brookfield viscometer, Model LVT, Spindle 7, 0.05 RPM. The cream is packaged into tubes or jars by methods known to those skilled in the art. All steps in the preparation and packaging are performed under aseptic conditions. The active agent is delivered onto the skin. Product is used for long periods of time for extended release of methylnicotinate onto skin.
Previous Patent: Composition for external application
Next Patent: Use of a compositon containing an effective quantity of at least one ion chelating agent for increas...


Paul was killed because she "fussed too much" at the grandson she had raised since age 2, prosecutors and police say. She expected a clean room and homework done, and for that she opened the door to her home after work to bullets that ripped her to pieces.
The bullets came from a gun owned by her husband, kept unlocked on a bedroom shelf next to a box of bullets.
The box of bullets had the grandson's fingerprints on it, prosecutors say.
The guns were stolen from Mack Paul, who police say also had been targeted to die. He was described by prosecutors as "the luckiest man alive" for not entering his home where the three lay in an ambush.
He was outside in a shed, having stopped there when he got home from work.
So now all three blame the others.
Clayton Eli Watts, the alleged mastermind grandson who didn't like rules so he wanted his grandparents dead.
Marqueas Buchanan, the friend from Chester High School whom Watts allegedly had asked for as long as two years to handle the killings.
And Shaiderius Cohen, the alleged triggerman whose lawyer and family now say confessed under duress and is being used as a fall guy by the other two suspects.
Prosecutors say Cohen was recruited by Buchanan to shoot Jimmie Paul because Buchanan was too scared to do it himself. Cohen's attorney, Leah Moody, even used the term "finger-pointing" in court.
Moody, after blaming the other two guys, then blasted police, saying Cohen's confessions were made "under duress" and had been "coerced" without her present.
"My nephew is not the shooter," Cohen's aunt, Kashonda Mobley, said after court. She said Watts and Buchanan are working together to make Cohen out to be the triggerman.
"They are trying to throw it on the other guy who was not even there," Mobley said.
Chester County Sheriff Alex Underwood denied after court that police had coerced Cohen's statements. Cohen voluntarily waived his rights and gave the statements, Underwood said.
Prosecutors said in court that Watts brought in Buchanan, who then brought in Cohen, who had admitted he was there and that he shot Jimmie Paul.
Cohen "pops up from behind the furniture and unloads on Mrs. Paul," Barfield said in court.
Then Cohen traded the gun "for some dope," Barfield said.
The murder weapon remains unfound.
Not a nickel of the $10,000 supposed to be paid for killing two grandparents was ever paid. The crime ended in flight by two of the three after bullets flew, with the grandson lying on his bed, listening to music on headphones as his grandmother bled to death from a pierced neck, leg and heart on the kitchen floor.
After Watts admitted the plot to police, he told on Buchanan. Police found the other stolen gun, a 9-mm handgun, in Buchanan's school bookbag. Buchanan has a prior juvenile conviction for taking a knife to school, too.
Buchanan's lawyer, Cyrus Hinton, spoke in court about how Buchanan was not the shooter, was scared after the crime, and how "he was solicited" by Watts to do the dirty work. Buchanan never recruited anybody, he said.
"It is my understanding that Mr. Buchanan is a good kid," Hinton said.
Watts' lawyer, Nathan Sheldon, spoke in two courtrooms Wednesday as he pointed fingers toward Watts' co-defendants. Buchanan's initial confessions that Watts was the shooter were full of "lies," Sheldon said.
"He is trying not to implicate himself in this murder," Sheldon said of Buchanan.
Then Sheldon brought up how Watts had never met Cohen until that day, and it was Cohen who actually did the shooting.
Prosecutors scoffed at all the claims being thrown around in the first courtroom attempts to blame the other guys.
All three were involved, Barfield said, from the time Watts hatched the plan to kill his grandmother, to his repeatedly asking Buchanan to handle the slaying for a price, to Buchanan's finding Cohen, who was more than willing to shoot for money.
All three are adults. Murder for hire is an adult crime. It carries up to life in prison upon conviction.
He declined after court to say what those offers will be, but it seems clear that the offer will be to plead guilty to murder, which carries 30 years to life in prison. Then maybe, just maybe, there will be a chance that one, two, or all three of these defendants might not end up dying in a prison.
Unlike Jimmie Paul, who died on a kitchen floor, shot in the neck, shoulder, leg and heart.
The same heart she had opened up to raise the grandson accused of plotting to kill her.


text:
Coming in November
Proposed amendment to the Florida Constitution, which will appear on the ballot this November:
BE IT ENACTED BY THE PEOPLE OF FLORIDA THAT:
A new section for Article I is hereby created to add the following:
Inasmuch as marriage is the legal union of only one man and one woman as husband and wife, no other legal union that is treated as marriage or the substantial equivalent thereof shall be valid or recognized.
I have so many objections to this amendment that I'm not sure where to begin.
Sorry, I lied. I know exactly where to begin. (There's a great blog post and discussion here, if you're interested.)
This is a horrible amendment. It not only eliminates the possibility of gay marriage laws (either by statute or case law), but it also makes a more conservative domestic partner law impossible. If that were not bad enough (and it's more than bad enough), it also could undermine the rights of unmarried, heterosexual couples. Companies could be banned from allowing unmarried couples to purchase health insurance (unless they both work for the same company, and are willing to pay for two separate policies). Domestic partner registries (which allow partners to stay with loved ones before and after surgery in the hospital) could be in jeopardy.
This amendment isn't just about protecting marriage, whatever that means. It's about setting aside a group of people, making them second class citizens, and punishing them. Incredibly, it's saying the status quo isn't nearly intolerant enough.
Think of the last part of the amendment language "… no other legal union that is treated as marriage or the substantial equivalent thereof shall be valid or recognized." Imagine how this broad language could be interpreted by conservative justices. Think of the slippery slope this amendment puts us on. Say these two words to yourself: "institutionalized persecution." Think about what that means. Ask yourself if the amendment rises to this level, and even if you think it doesn't, ask yourself if you want the final word on state law to head in this direction.
It's probably no surprise that I find the unabashed, wide reaching bigotry of the proposed language chilling. If you live in Florida, I hope you'll join me in voting NO in November.
One web:
http://www.floridaredandblue.com/
Beyond paper or plastic
Back out through the genetic minefield
I've never been able to figure out how giving rights to one group takes away rights from another. There is no pie being carved here. I am really glad I live in Canada, at least for the moment.
However, when our Prime Minister (a conservative) took office he toyed with the idea of trying to get rid of our law allowing gay marriage. Apparently, it wasn't wise politically for him to do so, and the matter was dropped. But he wanted to so we must be vigilant because what we've learned about our PM is that he is a brilliant strategist, an extreme control freak (he won't even let his ministers make their own announcements), and he's a social conservative who has managed to hide this behind fiscal conservatism. He scares me.
Good luck in November!
Yeah, it's the usual suspects. I could be wrong, but I think the guy who organized the petition drive (to get the amendment on the ballot) is the Florida version of James Dobson.
The two biggest contributers to the drive so far (contributing more than 75 percent of the half million raised) have been the Florida GOP and the Florida Catholic Conference (of Bishops).
As for Florida, we're an odd group of people. We can go either way in Presidential elections, and there are more registered Democrats than Republicans; but most of our statewide offices are held by conservatives, and somewhere between 70-80 percent of our state legislature is held by conservatives.
Florida is kind of like three states, each divided by big forrests/swamps. North Florida is sometimes referred to as lower Alabama, and is quite conservative. It's mostly rural, with a few population centers surrounding military bases. Central Florida (the "I-4 corridor" between St Petersburg, Tampa, and Orlando), along with southwest Florida (Ft Meyers and Naples) can be a little more moderate… but still leans conservative. There's a huge midwestern influence in central Florida, with a lot of folks from Michigan and Ohio. Miami is a different animal altogether. Most of the elected liberals (relatively speaking) come from Miami, and it's where most Democrats running for statewide or national office go for fundraising (by contrast, they might not make it out of Jacksonville or Pensacola alive).
Knowing some of the folks here, the amendment drive is not a surprise. I'm ashamed… but not surprised. I don't know if it's still true, but in 2005 we were the only state in the U.S. with a law on the books that banned gay adoption.
How despicable is that? We've decided that it's better for kids to rot in an overburdened foster-care system than be adopted by a loving gay or lesbian couple. The law got a little bit of coverage in the national news a few years ago when a challenge went as far as the supreme court, but they turned down the case… allowing the lower court's ruling to stand which upheld the law.
It's one of the reasons we've often talked about moving (never seriously though – we can't afford to – besides, somebody's gotta stick around to try and balance things out)
Is the religious right behind the push? I guess I wouldn't be surprised if this was an amendment in South Carolina or Mississippi, but it surprises me that Florida would be considering it. Am I way off base here?
We passed an amendment in 2006 which made it harder to pass amendments, but I haven't seen any polling data yet to see if this one has a chance of reaching the higher threshold. I have no idea which way it will go, but I hope Stephen's right.
I'm hoping the record turn out for some of the Democratic primaries so far this year is a good omen.
OMG this is just horrible. I really want someone to explain to me how two gay pr straight people sharing a bed and expenses and loving each other even when the other person is being a goof, puts my marriage in jeopardy
Scary. If this passes, you're going to live with it for a long time, because the only thing harder to do than change a constitution is to change it back again. Good to see there's a strong campaign underway to defeat it. And I can't help believing that the typical Floridian, despite his or her sensitivities, will see the amendment as discriminatory.
Give the gift of words.	Cancel reply


Welcome to your June Business Update!
Here we talk about when a business bids for a job, you usually draw up a quotation and the contract will be negotiated on that basis.
But large jobs, extended periods of supply, and most public sector contracts may need a more formal process of tendering.


text:
You are here: Home / HockeyBlog / Sunday: Kings Projected Lineup vs. VGK, Plus McLellan Quotes
Sunday: Kings Projected Lineup vs. VGK, Plus McLellan Quotes
In a season where the Kings have largely been forced to abandon their usual Tuesday-Thursday-Saturday home schedule used for decades, it shouldn't come as much of a surprise that one of the occasional second-half of the season afternoon games is being played at 3pm, instead of the more customary 1pm. It's just par for the course in a rather unique moment in time.
What coach Todd McLellan may be thinking regarding his lineup for LA's rematch with Vegas is anything but clear.
First and third lines? Sure, no problem. Easy to pencil in those six players. (Reminder: It's 2021, so nothing gets done in pen until after warmups. If there was ever a time when 'Wait for the song' was appropriate, this is it).
What happens on the second line ultimately impacts what happens with the fourth line. Where will Jeff Carter play was the question heading into Friday. That remains somewhat a mystery, as does the placement of Adrian Kempe and a few other forwards. We're willing to take a wild swing at it and see where things land.
Then again, McLellan could just opt to go with 11 forwards and 7 defensemen again, which would throw much of this out the window.
LA Kings projected lineup vs. the Vegas Golden Knights
Iafallo – Kopitar – Brown
Grundstrom – JAD – Moore
Kempe – Vilardi – Carter
Athanasiou – Lizotte – Luff / Wagner
Anderson – Doughty
Bjornfot – Roy
Maatta – Walker
Petersen (starter)
Other players available:
Austin Wagner
Kurtis MacDermid
Not available:
Martin Frk (IR)
The taxi squad is currently comprised of Michael Amadio, Daniel Brickley, Drake Rymsha, and Troy Grosenick
Although the Kings opted to skip morning skate and media availability this morning, McLellan did share the following comments after practice on Saturday:
On his use of 11+7 in the last game vs. Vegas
The odd-man out the last little bit has been MacDermid. When he's been in, he's actually played quite well, so we didn't want to lose him. We wanted to keep him up and running. It gave some of our other players opportunities for more minutes up front. It may be something we do more of as we go forward.
On if he plans to return to a fairly even Quick-Petersen rotation now that both guys are healthy and available
It's certainly something that we believe in. We just play so many games in so few nights that if you don't have two goaltenders that can take the net and perform at a high level, I think you're in trouble. Right now, we have two. We want to keep them fresh, keep them rested. Some of the nights that they've had here lately, Cal in particular, have been pretty taxing. A lot of shots on goal, so having Quickie healthy is a real good thing.
On what more he needs from Jeff Carter right to have him being as effective as he was earlier in the season
Carts has been a guy that's moved around a little bit too. When we look at the center ice position, he's had different centermen here over the last two or three games. He's been on different lines, starting yesterday. Carts has a tremendous amount of value that nobody on this call sees other than me doing my talking because I'm in the locker room, I'm on the bench. His ability to make others feel comfortable — forget about his play — is invaluable. He sells the message very well, from us through the team. He has the respect of the older players, as well as the younger players. On the ice, I thought he used his speed more [on Friday] than he has in the past. He looked a little fresher. He's getting chances. His hands and his shot, just polish that up a little bit more. He still has the ability to be very effective and he will continue to be as the year goes on.
On the defensive pairings staying fairly consistent when everybody is healthy
We would like to keep those pairs together as long as we possibly can. I think they've learned to read off of each other. It doesn't mean it's perfect, it doesn't mean that they don't make mistakes. They communicate with each other on the bench, they have cues that they read off of, body language that they can sense from each other right now. The common pairs on the back end, I believe is a good thing. Lefty-righty is also a good thing. It doesn't always work that way, but in today's game I think when you look at the top teams, they have common pairs that they're really comfortable running. Even after a bad night, they're willing to throw them back out there.
On letting young players sit vs. letting them work through it and managing their confidence
There is a fine line. Having young players come out of the lineup and reset themselves, and watch a game, sit down with the coaching staff without any pressure to go back out there and perform the next night, learn visually, talk things through is valuable. We don't enjoy pulling players out of the lineup and and sitting them, especially younger players that are maybe a little more fragile than the older ones. Sometimes it's a really, really good thing for them. Nobody thinks that at the time, certainly the player doesn't. Sometimes the fans don't, the media doesn't, and it can stir things up. It's often the right thing to do. There are times where our young players may need that. It may get to that point. It doesn't mean they can't play, won't play, and won't be very good players. It's just a reset mechanism that can be used.
On taking minutes away from players, including Vilardi and others
There's different lengths of rope for everybody. It's part of being an entry-level player, and understanding game management situations. We can talk about it, we can teach it, and we can throw them back out again and again. At some point, there has to be some responsibility for it. Among the older players, Kopi is going to get a lot more rope than Gabe is or Kempe is, or really anybody is on our team. That's just the way it works. He's earned the right to get that. It doesn't mean I'm not hard on him. It doesn't mean I don't hold him accountable amongst the group. He just gets more rope because he's earned the right to have that rope. There's a wide range of rope on the team. Not everybody is treated equal. That's just the way it is, but everybody is treated fair. That's the way it has to be.
Latest News on Contract Situations for Handful of LA Kings
Filed Under: HockeyBlog, Kings, NHL Tagged With: hockey, Kings, lineup, McLellan, NHL, projection


Who Says I Need Saving? Clip from I Had a Bloody Good Time at House Harker. See the movie exclusively on Amazon, Friday the 13th.
Follow us on Facebook for more updates and behind the scenes: http://facebook.com/HouseHarker.


Looking for Gentle Professional cleaning in Depew? For an appointment at Gentle Dentistry of Lancaster call our office today at 716-652-7080 or make an appointment today.
Gentle Dentistry of Lancaster in Depew, New York has a dedicated team of professionals on board to evaluate all of your dental needs. A good oral health has a great impact on your overall health. If you have any questions regarding our services or would like to come in for a consultation and quote, contact us today to schedule an appointment.


LOOKING FOR SOME R & R in the Northwoods? IDEAL and very picturesque 3.33 acres on Peshtigo Lake in Forest County and in the city of Crandon. Great place to build your retirement home or maybe a recreational get-a-way. This lot is wooded and a great place to build your dream home. Peshtigo Lake is a 147 acre lake located in Forest County. It has a maximum depth of 4 feet. Visitors have access to the lake from a public boat landing. Fish include Panfish, Largemouth Bass and Northern Pike. Lake known for barefoot ski championship events. Escape to the Northwoods today!
The details on N RAILROAD AVENUE: This land located in Crandon, WI 54520 is currently for sale for $59,900. N RAILROAD AVENUE is a – square foot land with – beds and – baths that has been on Estately for 211 days. This land is in the attendance area of Crandon Elementary School, Crandon Middle School, Crandon High School, and Crandon Alternative Resource School (Cars).